Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
100%(4 trials)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_2
2
40%
Ph phase_3
1
20%
Ph phase_4
1
20%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Other(1)

Detailed Status

Completed4
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)
N/A1 (20.0%)

Trials by Status

completed480%
suspended120%

Recent Activity

0 active trials
Showing 5 of 5
suspendednot_applicable

Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD

NCT07541378
completedphase_2

Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis

NCT02563899
completedphase_4

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02236611
completedphase_2

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

NCT02673619
completedphase_3

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

NCT02207829

Clinical Trials (5)

Showing 5 of 5 trials
NCT07541378Not Applicable

Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD

Suspended
NCT02563899Phase 2

Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis

Completed
NCT02236611Phase 4

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT02673619Phase 2

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

Completed
NCT02207829Phase 3

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5